Table 2.

Subsequent second-line anticancer treatments and disease progression in the second-line treatment.

	Patients with liver metastasis		Patients with lung metastasis
Treatments, n (%)	Palbociclib + letrozole (n=123)	Letrozole (n=75)	Palbociclib + letrozole (n=257)	Letrozole (n=171)
First-line treatment only*	49 (39.8)	28 (37.3)	125 (48.6)	67 (39.1)
Any second-line treatment received†	74 (60.2)	47 (62.7)	132 (51.4)	104 (60.8)
CDK4/6 inhibitor	22 (29.8)	23 (48.9)	48 (36.4)	63 (60.6)
Chemotherapy	26 (35.1)	6 (12.8)	37 (28.0)	14 (13.5)
Endocrine therapy alone	8 (10.8)	14 (29.8)	24 (18.2)	20 (19.2)
Other anticancer treatment	21 (28.4)	7 (14.9)	32 (24.2)	15 (14.4)
Second-line disease progression	37 (50.0)	20 (42.6)	69 (52.3)	47 (45.2)

CDK4/6=cyclin-dependent kinase 4/6.

*Includes patients who continued treatment, died, or were censored in the first-line setting.

^†Patients could have received >1 category of second-line treatment.